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Abstract
Background: Absence of pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) correlates
with poor long-term survival in patients with triple negative breast cancer (TNBC). These incomplete treatment
responses are likely determined by mechanisms that enable cancer cells to resist being killed. However, the detailed
characterization of a drug-resistant cancer cell state in residual TNBC tissue after NACT has remained elusive.
AKT1low quiescent cancer cells (QCCs) are a quiescent, epigenetically plastic, and chemotherapy-resistant
subpopulation initially identified in experimental cancer models. Here, we asked whether QCCs exist in primary
tumors from patients with TNBC and persist after treatment with NACT.
Methods: We obtained pre-treatment biopsy, post-treatment mastectomy, and metastatic specimens from a
retrospective cohort of TNBC patients treated with NACT at Massachusetts General Hospital (n = 25). Using
quantitative automated immunofluorescence microscopy, QCCs were identified as AKTlow/H3K9me2low/HES1high
cancer cells using prespecified immunofluorescence intensity thresholds. QCCs were represented in 2D and 3D
digital tumor maps and QCC percentage (QCC-P) and QCC cluster index (QCC-CI) were determined for each
sample.
Results: We showed that QCCs exist as non-random and heterogeneously distributed clusters within primary breast
tumors. In addition, these QCC clusters persist after treatment with multi-agent, multi-cycle, neoadjuvant
chemotherapy in both residual primary tumors and nodal and distant metastases in patients with triple negative
breast cancer.
Conclusions: These first-in-human data potentially qualify AKT1low quiescent cancer cells as a non-genetic cell state
that persists after neoadjuvant chemotherapy in triple negative breast cancer patients and warrants further study.
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Background
Triple negative breast cancer (TNBC) is more commonly
diagnosed in younger and African-American women, is
associated with worse recurrence-free survival and worse
overall survival, and has fewer effective treatment options,
compared to hormone receptor-positive or human epider-
mal growth factor receptor 2 (HER2)-positive breast
cancer [1, 2]. For patients with localized TNBC, neoadju-
vant chemotherapy (NACT) is primarily used to increase
the success of breast conservation therapy [3]. This
neoadjuvant approach also offers an attractive paradigm
for evaluating biomarkers of resistance to chemotherapy,
since pre-treatment tumor biopsies can be compared to
post-treatment mastectomy specimens and pathologic
complete response (pCR) to NACT correlates with better
clinical outcomes in TNBC [4]. While pCR rates reported
in clinical trials vary depending on the definition used,
tumor type, and specific neoadjuvant treatment, poor
pathologic response despite NACT occurs in 40–60% of
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patients with TNBC [5]. Absence of pCR after neoadju-
vant chemotherapy is presumably determined by mecha-
nisms that enable tumor cells to resist being killed. A
small number of tumor-specific genetic alterations have
been recently described in localized TNBC after NACT
(e.g. TP53, MCL1, MYC), although actionable targets
remain infrequent [6]. Alternative mechanisms that give
rise to drug-resistant cell states such as quiescence or
altered epigenetic profile have also been postulated,
although the detailed characterization of a putative quies-
cent, drug-resistant, cancer cell state in residual TNBC
after NACT remains elusive [6–9].
We previously reported that MCF7 (estrogen receptor
positive (ER+)) and MDA-MB-231 (triple negative)
breast cancer cell lines (among other tumor types) are
capable of dividing asymmetrically to form quiescent,
AKT1low cancer cells (QCCs) in response to decreased
integrin-β1 (ITGB1) signaling from the microenviron-
ment both in vitro and in vivo [10, 11]. We have
previously shown that these AKT1low slow proliferators
also express other markers of quiescence in being
ROSlow, MKI67low, MCM2low, H3K9me2low and
HES1high [10, 11]; QCCs are intrinsically resistant to
cytotoxic chemotherapy and also elaborate CD63+ exo-
somes that increase the fitness of surrounding, more
rapidly cycling, cancer cells [12]. Moreover, we have
found that QCCs exhibit many properties ascribed to
cancer stem cells, including an increased tumor-
initiating capacity and epigenetic plasticity that contrib-
utes to cancer cell heterogeneity [13]. Together, these
experimental data suggest that AKT1low quiescent
cancer cells may play a role in resistance to cytotoxic
therapy and tumor progression.
We previously identified QCCs in a small number of
primary breast tumors of different subtypes (ER+, triple
negative, HER2+) before and after neoadjuvant chemo-
therapy with indirect immunofluorescence confocal
microscopy (n = 5) [11]. While this approach is used
routinely to identify protein-based biomarkers in
formalin-fixed paraffin-embedded (FFPE) human tumors,
it is constrained by limited multiplexing, high background,
restricted sampling of tumor areas and subjective deter-
mination of positive/negative thresholds [14]. In contrast,
quantitative immunofluorescence, using a tyramide-
signal-amplified (TSA) staining protocol coupled to multi-
spectral imaging and automated tissue segmentation,
allows for the objective detection of multiple intracellular
protein targets within defined regions of interest and en-
ables accurate and reproducible assessment of individual
cell markers and cell states in a wide variety of human
tumor samples [15–18]. Here, we used TSA multiplexed
immunofluorescence staining coupled to automated
multispectral imaging and computational analysis to iden-
tify AKT1low (AKTlow, H3K9me2low, HES1high) QCCs in
tumors from patients with TNBC. We tested the hypoth-
esis that QCCs persist in primary and metastatic TNBC
breast tumors after NACT.
Methods
Patient cohort and samples
We identified a retrospective cohort of patients with lo-
calized TNBC at Massachusetts General Hospital, who
underwent neoadjuvant chemotherapy between 2010
and 2014. Tissue samples from 25 patients (10 biopsy
samples, 20 mastectomy samples, 4 metastatic samples)
were retrieved under an Institutional Review Board
(IRB)-approved discarded-tissue protocol (2009P20032)
as summarized in the consolidated standards of report-
ing trials (CONSORT) diagram (Fig. 1a); of these 25
patients, 8 patients had matched biopsy and mastectomy
samples available for analysis, and of these 8 matched
patients, 4 had tumors that underwent pCR, and the
remaining 4 patients had primary tumors with residual
disease after NACT, which were evaluated for QCCs.
One patient with a paired biopsy and mastectomy
sample with residual disease also had a metastatic tissue
sample available for analysis. An additional 2 unmatched
biopsies, 12 unmatched mastectomies and 3 unmatched
metastases were also available for QCC analysis.
Throughout this report, the term sample refers to a
single 4-μm tissue section from a single patient tumor.
Pathologic assessment of patient samples
Clinical and pathological information (Fig. 4a) was
extracted from the medical record. Residual cancer
burden was graded, using standard criteria [19] for as-
sessment, on a representative H&E-stained section from
each post-treatment mastectomy block, by our study
pathologist (DS), who was blinded to QCC results.
Selection of QCC markers
We have previously shown that QCCs can be reliably
identified in vitro and in FFPE human tissues using the
antibody profile: pan-AKTlow, H3K9me2low, HES1high
[11]. In choosing markers with which to identify QCCs
in FFPE patient tissues, we were limited by existing im-
munofluorescence multiplexing bandwidth to three
markers. Therefore, we selected the minimum set of
markers that represented canonical features of QCCs,
such as quiescence, which we had previously described
in vitro [10–12]. To maximize specificity, we opted for
at least one marker that was upregulated and another
that was downregulated in QCCs.
Tyramide-signal-amplifying immunofluorescence (TSA-IF)
labeling
We undertook TSA-IF labelling of FFPE patient tissue
sections as previously described and summarized in Fig. 1
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[18]. Primary antibodies were applied iteratively followed
by secondary antibody conjugated to horseradish perox-
idase (HRP), after which TSA-conjugated fluorophores
were applied. Primary antibodies used were, iteratively,
H3K9me2 (1:150, abcam ab1220), pan-AKT (1:3000, Cell
Signaling 4961, C67E7), and HES1 (1:3000, EMD Milli-
pore AB5702). Primary antibodies had been previously
independently validated for target specificity [20–22].
This was followed by a secondary antibody conjugated
to HRP (SuperPicture Polymer Detection Kit, Life
Technologies), and TSA conjugated to a fluorophore
(fluorescein isothiocyanate (FITC), cyanine (CY)3, CY5,
respectively, at 1:50 dilution, Perkin Elmer), with inter-
vening wash steps. An alternative iteration of primary
antibody application (pan-AKT ➔ H3K9me2 ➔ HES1)
was used to confirm target specificity and absence of
primary antibody cross-reactivity (Additional file 1: S2).
We applied 4',6-diamidino-2-phenylindole (DAPI) as a
nuclear counterstain. Staining was completed in batches
of 10 and slides were mounted using ProLong Diamond
Antifade Mountant without DAPI (ThermoFisher
Scientific).
To examine the effects of batch-to-batch staining
variability, we used 4 untreated primary breast tumors
Fig. 1 Detailed workflow for AKT1low quiescent cancer cell (QCC) identification using tyramide signal amplified immunofluorescence (TSA-IF)
automated microscopy coupled with computational image analysis. a Consolidated standards of reporting trials (CONSORT) diagram for QCC analysis
of tissues from a cohort of patients with triple negative breast cancer (TNBC). b Scheme demonstrating steps in TSA-IF staining of tumor sections.
c Scheme demonstrating steps for automated image acquisition using the Vectra platform (Perkin Elmer) and inForm software. Individual images at ×
20 undergo spectral isolation for each fluorescent marker (4',6-diamidino-2-phenylindole (DAPI), pan-AKT, H3K9me2, HES1) (i) to allow for generation of
a tissue mask that segregates tumor and stroma (ii) followed by a cellular segmentation (iii) that allows for extraction of fluorescence intensities for
each cellular segment e.g. nucleus, cytoplasm. d Scheme demonstrating establishment of fluorescence intensity thresholds for each marker (pan-AKT,
H3K9me2, HES1) and identification of QCCs based on pre-established thresholds to allow for generation of digital tumor maps and determination of
QCC percentage and QCC cluster index. NACT neoadjuvant chemotherapy, ER+ estrogen receptor positive, HRP horseradish peroxidase
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(control tumors 1–4, Fig. 3b). Control tumors 1 and 2
underwent contiguous (4 μm apart) sequential section-
ing (n = 2) and sections were stained in different batches.
Control tumor 4 underwent contiguous sequential
sectioning (n = 3) and all sections were stained in the
same batch. Control tumor 3 underwent non-contiguous
(>4 μm apart) sequential sectioning (n = 5) and each
section was stained in a different batch containing
patient samples, to control for inter-batch variation.
Confocal microscopy
To provide a high-resolution example image of a QCC,
section 17 from control tumor 3 was imaged using a
Nikon Ti confocal microscope at × 60 magnification
(Fig. 2a). Merged and single-color images were labelled
using Image J [23].
Spectral imaging and multispectral analysis
Matched H&E-stained slides from each tissue block
were reviewed by a collaborating pathologist (YH) to
confirm the presence of tumor cells in each tissue block.
Multispectral imaging of sections was undertaken as
previously described [18]. TSA-IF-stained slides were
scanned using the Vectra slide scanner (V2.0.8, PerkinEl-
mer) with appropriate fluorescent filters. A scanning
protocol was created for multispectral imaging and ap-
plied to all slides uniformly (Fig. 1c). Regions of interest
were manually selected within the Vectra protocol using
low-power field previews of the whole slides as reference
and scanned to generate a multispectral image at × 20
magnification. Those images with <1% tumor compo-
nent or >70% technical artifacts (e.g. significant tissue
folding, air bubbles, or loss of tissue) were excluded.
Single-stained (individual marker with specific fluoro-
phore e.g. only pan-AKT with FITC) TNBC primary
tumor sections and blank control slides were used to
build a spectral library for each batch (Fig. 1c). InForm
V.2.1.1 software (CRi) was used to analyze the spectral
images. An InForm tissue and cell segmentation algo-
rithm was developed by selecting representative areas
from a training set of 15–20 images, to classify tissue
into “tumor” (tumor epithelium) and “stroma” (tumor
adjacent tissue) categories. Nuclear segmentation was
based on the DAPI signal, with the cytoplasm estimated
up to 6 pixels outer distance to nucleus. Tissue classifi-
cation and cell segmentation were manually reviewed by
our study pathologist (YH) to ensure appropriate
classification.
Computational and statistical methods
Raw fluorescence intensity data processing, analysis, and
graphical representation of the resulting digital tumor
maps were done using R statistical computing software
(R Core Team (2015), R Foundation for Statistical
Computing, Vienna, Austria).
QCC percentage (QCC-P) for the biopsy, mastectomy
and metastasis samples was determined from a single
tissue section taken from a single tumor. For groups
(biopsy samples or mastectomy samples) mean ± SD
values are reported. The difference in mean QCC-P
between the pre-treatment biopsy group and the post-
treatment mastectomy group was tested using the un-
paired t test with two-sided p < 0.05 as the critical value.
The difference in mean QCC cluster index (QCC-CI)
between the biopsy group and the mastectomy group
was tested using the unpaired t test with two-sided p <
0.05 as the critical value. Correlation between QCC-P,
QCC-I, tumor cellularity was estimated using Pearson’s
correlation coefficient.
We undertook a post-hoc power calculation based on
our sample size of 10 biopsy samples and 16 mastectomy
samples. The difference in mean QCC-P between the bi-
opsy group and the mastectomy group was 0.567 ± 0.25
and, assuming a type 1 error rate of 0.05, the power of
this study to detect this difference was 0.73.
Determination of immunofluorescence intensity
thresholds
The average pixel intensity data for the nuclear compart-
ment were used for the H3K9me2 signal, while average
pixel intensity data for the cytoplasm compartment were
used for the HES1 and AKT. Untreated primary breast
tumors (n = 4) were designated “control tumors 1–4”
and used as a training set to determine fluorescence in-
tensity thresholds.
Using this control tumor training set, we first asked if an
absolute threshold of fluorescence intensity could be used
for each marker (pan-AKT, H3K9me2, HES1) to define
QCCs. We plotted the proportion of cells against fluores-
cence intensity from two sequential sections stained simul-
taneously (control tumor 4, Additional files 2: S1A and
S1B, respectively). The proportion of cells that expressed
each QCC marker (e.g. HES1) at a given fluorescence in-
tensity was not the same in sequential sections (Additional
files 2: S1A and S1B, respectively). This suggested that ab-
solute fluorescence intensity thresholds for determining
QCCs would not be reproducible across different tumor
samples.
Using the control tumor training set, we then asked if
a relative threshold could be used to determine fluores-
cence intensity. We chose three relative thresholds: 25%,
33%, and 50%. For example, at the 25% threshold, cells
were called QCCs if they fell into the 75th percentile of
fluorescence intensity for HES1 and the 25th percentile
of fluorescence intensity for pan-AKT and H3K9me2,
respectively, in that section. We applied these three
thresholds to our training set control samples (control
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tumors 1–4, Additional file 2: S1C-E) We found a pro-
portional increase in mean QCC-P and QCC density
(QCC-D) (QCC-P per × 20 field of view) with increasing
threshold, suggesting no natural cutoff could be detected
at the thresholds tested in these control tumors.
Together, these data suggest that there was a continuous
expression of each marker (pan-AKT, H3K9me2, HES1)
with the absence of a natural cutoff for identifying QCCs.
The lack of a natural cutoff has been previously reported
for other markers associated with cell proliferation, such
as Ki67 [24]. In order to balance specificity and sensitivity,
QCCs were defined as those cancer cells expressing the
top 25% of fluorescence intensity values for HES1
(HES1high) and the bottom 25% of fluorescence intensity
values for both pan-AKT (AKTlow) and H3K9me2
(H3K9me2low) using this microscopy approach.
Digital tumor maps were generated by de-convoluting
cell geographical coordinates from the relative position
of each × 20 magnified image from each section. A single
cell Cartesian coordinate system was created for each
section and used to accurately represent tumor cell
geography in a single map. For improved visualization of
QCCs in digital tumor maps (red dots) red hue was
maximized using Adobe Photoshop CC 2017 software.
Definition of QCC-P and QCC-D
We defined QCC-P as the proportion of QCCs in the
total cancer cell population per section. We also defined
QCC-D as the QCC-P per × 20 field of view (FOV).
QCC-P for the biopsy, mastectomy and metastasis sam-
ples was determined from a single tissue section taken
from a single patient.
Definition of QCC-CI
The QCC-CI was defined as the proportion of QCCs
among the 100 nearest tumor cells for each QCC in a
section. Cells with fewer than 100 neighbors in a reason-
able proximity (a window of +/- 500 coordinate units in
each axis) were discarded. The final QCC-CI for each
section was computed by averaging the cluster index for
each QCC in that section. Class-label permutation was
used to computationally determine the statistical signifi-
cance of these results. For each sample, 1000 random
sets of k cells, where k is the number of QCCs in the
sample, were selected and for each one of these k sets of
cells a QCC-CI was computed. Once we collected all
1000 permutation-based QCC-CI for a sample, empirical
p values were obtained by comparing them to the score
for that sample.
Results
In order to test the hypothesis that QCCs persist after
NACT in patients with TNBC, we first used a training
set of primary breast tumors (control tumors 1–4) to
develop a QCC identification platform involving TSA-IF
labeling of FFPE tissue sections, spectral imaging, and
computational analysis as summarized in Fig. 1.
QCCs are distributed heterogeneously within primary
breast tumors
Using the QCC identification platform, we were able to
identify and represent AKT1low, H3K9me2low, HES1high
QCCs (red dots) and other cancer cells (blue dots) as 2D
digital tumor maps of whole sections from TNBC and
other breast tumors based on Cartesian coordinates
within each section (Fig. 2a, b, c). For clarity, areas of
stromal infiltration, necrosis, or poor image quality were
excluded from these maps. Initial inspection of these 2D
maps suggested that QCCs displayed a high degree of
spatial heterogeneity. Our tumor map approach also
enabled us to determine the topographical arrangement
of QCCs by analyzing sequential sections from tumors.
Figure 3a shows digital tumor maps of five sequential
but non-contiguous sections from a representative,
untreated, TNBC tumor (control tumor 3), arranged in a
3D stack according to the orientation of each within the
primary tumor block. In this particular specimen, QCCs
were found in the periphery of some sequential sections
(black arrows, Fig. 3a) but not others (white arrows,
Fig. 3a).
To ask whether QCCs were enriched in specific
regions of a given tumor, we defined QCC-P as the
proportion of QCCs in the overall cancer population
per section. We also defined QCC-D as the QCC-P
per × 20 FOV. We noted a tremendous variance in
QCC-D within each section (box and whiskers plot),
but found that QCC-P (red bars) was relatively con-
sistent across sections and between tumors (Fig. 3b).
Furthermore, QCC-D was not directly proportional to
the total cancer cell density (Additional file 3: S3F).
This heterogeneity in QCC location and variation in
QCC density suggested that QCC topography might
not be determined solely by cancer-cell-intrinsic cues,
consistent with prior experimental findings that QCCs
arise through irregular interaction between cancer cell
surface integrin-β1 receptor and extracellular matrix
proteins [10, 11].
The heterogeneous localization of QCCs likely was not
a technical artifact, because the identification of QCCs
required high HES1 signal concurrently with low AKT
and H3K9me2 signal, which would not occur due to ir-
regularities in antibody penetration or antigen retrieval
alone. In addition, careful study of all tumors did not re-
veal consistent patterns in the geographical localization
of QCCs.
To test whether the variation in QCC percentage and
QCC geography between specimens was due to batch-to-
batch staining variability, we examined QCC-P, QCC-D,
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and QCC geography in sequential sections from control
tumors 1, 2 and 3 (stained asynchronously) and sequential
sections from tumor 4 (stained synchronously)
(Figs. 3a and b). We found that QCC percentage (red
bars, Fig. 3b) was more similar between contiguous
sections (control tumors 1, 2, 4, Fig. 3b) than non-
contiguous sections (control tumor 3, Fig. 3b), regard-
less of synchronous (control tumor 4) or asynchron-
ous (control tumors 1, 2, 3) staining. This suggested
that variation in QCC-P between sections more likely
reflected biological variability in QCC location within
the tumor rather technical variation in staining. In
addition, QCCs appeared to be concentrated in geo-
graphic regions that extended across multiple sequen-
tial sections stained asynchronously (control tumor 3,
black arrows, Fig. 3a). The identification of QCCs in
similar regions of sequential sections stained asyn-
chronously would be unlikely to happen in the
Fig. 2 AKT1low quiescent cancer cells (QCCs) are found in primary breast tumor tissue using quantitative immunofluorescence microscopy. a
White arrow points to an example of a QCC cluster from control tumor 3, section 17 by confocal microscopy at × 60; upper panel shows merged
image and lower panel shows single color images. b Upper panel shows the same QCC cluster as in a (red arrow) as × 20 composite image (pan-
AKT (green), H3K9me2 (yellow), and HES1 (red)). In the lower panel, the area shown in the × 20 image is represented as a digital tumor map
identifying the same QCCs (red arrow) shown in a with high fidelity. c An example of a whole-section digital tumor map for tumor 3, section 17,
where QCCs are shown by red dots and other cancer cells by blue dots. Image coordinates are listed on each axis. Red arrow points to the same
QCC cluster shown in a and b
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absence of consistent QCC labeling and identification
by the TSA-IF system.
QCCs cluster within primary breast tumors
Visual inspection of this non-random distribution of
QCCs suggested that QCCs may actually cluster with
other QCCs in untreated primary breast tumors. To fur-
ther test this hypothesis, we asked if a given QCC was
more likely to be found in proximity to other QCCs than
to other cancer cells within tumor sections. We defined
the QCC-CI as the probability that the nearest neighbors
of QCCs were QCCs, rather than other cancer cells (n =
100). We plotted the QCC-CI (bars) and QCC-P (orange
dots) for different tumor samples, ordered by increasing
QCC-P (Fig. 4a). Absent bars indicate samples for which
permutation testing was not significant.
Fig. 3 AKT1low quiescent cancer cells (QCC) are heterogeneously and non-randomly distributed throughout primary breast tumors. a Control tumor 3,
sections 8–23 arrayed sequentially as a 3D stack of digital tumor maps showing QCCs (red dots) and other tumor cells (blue dots). Stroma, areas of ne-
crosis or areas of poor image quality are excluded (gray areas). QCC percentage (QCC-P) for each section is shown on the left of each plane. QCCs are
found in the periphery of some tumor sections but not others (black arrows vs. white arrows). b Summary of QCC-P for each section of control samples
1–4 (red lines) with QCC-density (QCC-P for each × 20 field of view) represented by box and whisker plot for each section. Summary QCC-P and QCC
density for each whole tumor sample (mean of all available sections from that tumor) is indicated by bold labels (e.g. Control 3)
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Indeed, we found that QCCs were statistically more
likely to be found in proximity to other QCCs than
other tumor cells in all control primary tumors (black
bars, Fig. 4a). Furthermore, QCC-CI positively correlated
with QCC-P (R = 0.54) across all samples, suggesting
that even as QCC numbers increase they remain in close
proximity to other QCCs (Fig. 4b). QCC-CI did not
directly correlate with total cell numbers in each section,
however, suggesting that this observed clustering was
not simply a function of increasing tumor cellularity
(Additional file 3: S3E).
We then used the QCC identification platform to
analyze biopsy (n = 10) and mastectomy (n = 16) samples
from a retrospective cohort of patients with primary
A
B
Fig. 4 AKT1low quiescent cancer cells (QCC) cluster in primary triple negative breast cancer (TNBC) tumor sections and the likelihood of clustering
(QCC-cluster index (QCC-CI)) correlates with the QCC percentage (QCC-P). a QCC-CI for control samples (n = 4, black bars), pre-neoadjuvant
chemotherapy (NACT) TNBC primary tumor biopsy samples (n = 10, red bars), post-NACT TNBC primary tumor mastectomy samples (n = 15; 1 sample
was excluded due to insufficient QCCs to determine QCC-CI, green bars) and metastasis samples (n = 4, blue bars). QCC-P for each patient sample
(based on QCC-P of one section per sample) is shown by orange dots. Clinical and pathologic data for each patient is shown adjacent to each sample.
Each patient is identified by a unique identifier with sample type designated by the letter suffix e.g. patient BR10614-79 has a biopsy (BR10614-79-B),
post-NACT mastectomy sample (BR10614-79-Ma) and metastatic sample (BR10614-79-Me) available. Matched biopsy and mastectomy pairs with residual
disease after NACT are labeled bold. Biopsy samples with matched mastectomy samples that underwent pCR are underlined. A patient with matched
biopsy, mastectomy and metastasis samples is identified by bold italics. b QCC-CI correlates with QCC-P for control, biopsy, mastectomy and metastasis
sections (R = 0.54)
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TNBC that had been treated with NACT, to test the
hypothesis that QCCs in primary tumors persist after
NACT.
QCC clusters persist after chemotherapy in primary and
metastatic TNBC tumors
We compared QCC-P (orange dots) and QCC-CI (pre-
treatment: red bars; post-treatment: green bars) in
primary TNBC tumor samples before and after multi-
agent, multi-cycle neoadjuvant chemotherapy (Fig. 4a).
We found that QCC-P and QCC-CI were positively
correlated in pre-treatment biopsy samples (R = 0.89,
Additional file 3: S3B), and post-treatment mastectomy
samples (R = 0.37, Additional file 3: S3C), a finding that
was consistent with control samples (R = 0.74, Additional
file 3: S3A). This suggested that the relationship between
QCC clustering and QCC percentage was preserved
within primary tumors after chemotherapy. QCC-CI did
not correlate with total number of tumor cells, however,
further supporting the idea that QCC clustering was not
a function of the overall cellularity of the specimen after
chemotherapy (Additional file 3: S3E). QCC-CI and
QCC-P did not correlate with other clinico-pathologic
characteristics such as patient age, menopausal status,
BRCA status, tumor stage, pathologic response
(Additional file 4: S4), or type of chemotherapy (Fig. 4a).
Significantly, QCC-P appeared to increase after NACT
in post-treatment mastectomy specimens compared to
pre-treatment biopsies (Fig. 5a). Paired samples are
shown by dotted lines (Fig. 5a). This observation sug-
gested that after NACT, QCCs may comprise a larger
proportion of residual cells in the tumor, as compared to
pre-treatment tumor tissue, as illustrated in Fig. 5c.
However, given the limited sampling intrinsic to core
biopsy specimens, this finding will require further valid-
ation in larger cohorts. QCC-CI was preserved after
NACT in post-treatment mastectomy specimens com-
pared to pre-treatment biopsies (Fig. 5b). These data
further suggested that QCCs persist as clusters after
NACT (Fig. 5c). The increase in QCC-P was consistent
with either the preferential survival of QCC clusters
post-therapy (i.e. selection) or induction of the QCC
state by chemotherapy, but further studies are required
to distinguish between these two possibilities.
Fig. 5 AKT1low quiescent cancer cells (QCCs) in primary tumors from patients with triple negative breast cancer persist after multi-agent, multi-cycle neo-
adjuvant chemotherapy (NACT). a QCC percentage appeared to increase in primary breast tumor tissue after NACT (p= 0.017) Paired samples are shown
by dotted lines. b QCC cluster index is preserved in primary breast tumor tissue after NACT (p = 0.056). c Graphical summary of a and b showing that
QCC percentage and clustering persist in post-treatment primary breast tumors after treatment with anthracycline, taxane, platinum-based chemotherapy,
and mTOR inhibitors and VEGF inhibitors (red dots, QCCs; blue dots, non-QCCs)
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Finally, we asked whether QCC clusters also exist at
metastatic sites after treatment. We determined the
QCC-P and QCC-CI in four metastatic TNBC speci-
mens (Fig. 4a, blue bars). As in primary tumors, QCC-P
and QCC-CI in metastatic tumors were positively corre-
lated (R = 1, Additional file 3: S3D). QCCs were also
found in TNBC deposits within axillary lymph nodes
(BR10614-62, BR10614-79), brain (BR10614-65-Me) and
skin (BR10614-83-Me). Intriguingly, the QCC-CI and
QCC-P from a single patient with residual axillary
disease after NACT (BR10614-62) also appeared to be
significantly greater than that of other sites. These lim-
ited but provocative data were consistent with QCC
clusters existing not only within primary but also within
metastatic tumors.
Discussion
AKT1low quiescent cancer cells have varied cellular prop-
erties that are associated with chemotherapy resistance in
experimental models [10–13]. A previous study in tumor
samples from five breast cancer patients suggesting that
QCCs might survive NACT within human tumors was
limited by the use of manual microscopy and the small
sample size [11]. Here, we developed a quantitative im-
munofluorescence microscopy and computational analysis
platform to identify and characterize QCCs in clinical
tumor specimens, and applied this platform to study a lar-
ger cohort of TBNC patients treated with NACT.
For this and future tissue-based studies using quantita-
tive immunofluorescence, we defined QCCs as those
cancer cells concurrently expressing the 75th percentile
of HES1 fluorescence intensity and the 25th percentile of
pan-AKT and H3K9me2 fluorescence intensity, respect-
ively, in that sample. We found that QCCs cluster in
highly heterogeneous patterns within pre-treatment pri-
mary tumors. The non-random distribution of QCCs is
consistent with our prior experimental evidence that
micro-environmental effects may determine the QCC
state, although additional work is necessary to fully
explore this idea in human tumors. Given the degree of
QCC heterogeneity, future evaluation of multiple se-
quential contiguous sections from matched biopsies and
untreated whole tumor sections will be needed to define
the minimum number of sections necessary to accur-
ately represent the QCC-P for an entire tumor.
QCC clusters also appear to persist after multi-agent,
multi-cycle chemotherapy in primary tumors and syn-
chronous and metachronous nodal and distant metastases.
Patients in this cohort varied in age, menopausal status, ini-
tial disease stage, and BRCA status. These randomly se-
lected patients were also treated with anthracyclines,
taxanes, platinum-based therapy, and mTOR-inhibitors and
VEGF-inhibitors. Together, these data are consistent with
QCCs potentially representing a non-genetically
determined cell state that persists after combination
chemotherapy of various types at both primary and meta-
static sites.
The use of pre-specified fluorescence thresholds to iden-
tify QCCs eliminated bias in cell identification and
allowed us to quantify QCC-P in patient tumor samples.
In addition, representing QCCs and other cancer cells as
digital tumor maps allowed us to define the spatial rela-
tionships between QCCs and QCC clustering (QCC-CI).
This automated approach yielded striking information on
the geographical location, density, clustering, and hetero-
geneity of QCCs not readily apparent with the use of
standard, indirect immunofluorescence and manual mi-
croscopy. Given the modest numbers and retrospective
nature of our cohort, it was not possible to assess the as-
sociation between QCC-P and/or QCC-CI and patient
outcomes such as time to recurrence or overall survival,
but future studies will address these important issues. In
addition, multiplexing of additional markers should enable
further study of the relationship between QCC clusters
and other cancer and stromal cell subpopulations within
breast and other tumors both before and after treatment.
Conclusions
The mechanisms that allow TNBC tumors to survive neo-
adjuvant chemotherapy are incompletely understood. Evi-
dence suggests that proliferative heterogeneity may
contribute to primary chemotherapy resistance in patients
with TNBC. However, the identification of a putative quies-
cent, drug-resistant, cancer cell state in residual TNBC after
NACT has remained elusive. AKT1low quiescent cancer
cells are a quiescent, epigenetically plastic, and
chemotherapy-resistant subpopulation initially identified in
experimental cancer models. Here, we reproducibly dem-
onstrated the presence of QCCs in primary and metastatic
human breast tumors using automated, quantitative, im-
munofluorescence microscopy coupled with computational
and statistical analysis. We showed that QCCs exist as non-
random and heterogeneously distributed clusters within
primary tumors. In addition, these QCC clusters persist
after treatment with multi-agent, multi-cycle, NACT in
both residual primary tumors and nodal and distant metas-
tases in patients with TNBC. Together, these data poten-
tially qualify QCCs as a non-genetic cell state that persists
after NACT in TNBC patients, and warrants further study.
Additional files
Additional file 1: S2 Antibody target specificity is unaffected by
sequence of primary antibody application. Merged (right) and single color
(left) confocal microscopy images at × 60 of an untreated primary TNBC
tumor stained in an alternate sequence: pan-AKT ➔ H3K9me2 ➔ HES1
(c.f. standard sequence of H3K9me2 ➔ pan-AKT ➔ HES1) demonstrating
consistent cytoplasmic pan-AKT (green) and HES1 (red) staining and
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nuclear H3K9me2 (yellow) staining in an example QCC (white arrows).
(PDF 3624 kb)
Additional file 2: S1 Determination of fluorescence intensity thresholds
and staining reproducibility. For each marker (HES1, H3K9me2, pan-AKT)
the proportion of cells at a specific fluorescence intensity level was
different between sequential sections from control tumor 4, stained
simultaneously (S1A and S1B, respectively). QCC percentage (red bars)
and QCC density (box and whisker plots) in control tumors 1–4 increased
proportionally at 25%, 33%, and 50% thresholds (S1C, S1D, and S1E,
respectively). (PDF 2666 kb)
Additional file 3: S3 QCC-P and QCC-CI are positively correlated in control
samples and in biopsy and mastectomy samples after neoadjuvant
chemotherapy. Correlation of QCC-CI and QCC-P in control samples (A),
pre-treatment biopsy samples (B), post-treatment mastectomy samples (C),
and metastatic samples (D). E QCC-CI does not correlate with total number
of cancer cells in each sample. F QCC density (QCC-P per × 20 field of view)
in control samples does not positively correlate with cancer cell density
(cancer cells per × 20 field of view). (PDF 3045 kb)
Additional file 4: S4 QCC-P of pre-treatment biopsies and matched mast-
ectomy specimens with pathologic complete response after NACT is not sig-
nificantly different from QCC-P of pre-treatment biopsies and matched
mastectomy specimens with residual disease after NACT. Plot shows QCC per-
centage of pre-treatment biopsies (n= 8, blue dots) ordered by the pathologic
response of their matched post-treatment mastectomy specimens (residual
disease vs. pathologic complete response) p= 0.39. (PDF 731 kb)
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